VRTX
Income statement / Annual
Last year (2023), Vertex Pharmaceuticals Incorporated's total revenue was $9.87 B,
an increase of 10.51% from the previous year.
In 2023, Vertex Pharmaceuticals Incorporated's net income was $3.62 B.
See Vertex Pharmaceuticals Incorporated,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$9.87 B
|
$8.93 B
|
$7.57 B
|
$6.21 B
|
$4.16 B
|
$3.05 B
|
$2.49 B
|
$1.70 B
|
$1.03 B
|
$580.42 M
|
| Cost of Revenue |
$1.26 B |
$1.08 B |
$904.20 M |
$736.30 M |
$547.76 M |
$409.54 M |
$275.12 M |
$210.46 M |
$125.54 M |
$60.99 M |
| Gross Profit |
$8.61 B |
$7.85 B |
$6.67 B |
$5.47 B |
$3.62 B |
$2.64 B |
$2.21 B |
$1.49 B |
$906.79 M |
$519.43 M |
| Gross Profit Ratio |
0.87 |
0.88 |
0.88 |
0.88 |
0.87 |
0.87 |
0.89 |
0.88 |
0.88 |
0.89 |
| Research and Development
Expenses |
$3.16 B
|
$2.54 B
|
$3.05 B
|
$1.83 B
|
$1.75 B
|
$1.42 B
|
$1.32 B
|
$1.05 B
|
$996.17 M
|
$855.51 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$401.43 M
|
$352.58 M
|
$289.21 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$31.40 M
|
$24.50 M
|
$16.20 M
|
| Selling, General &
Administrative Expenses |
$1.14 B
|
$944.70 M
|
$840.10 M
|
$770.46 M
|
$658.50 M
|
$557.62 M
|
$496.08 M
|
$432.83 M
|
$377.08 M
|
$305.41 M
|
| Other Expenses |
$475.50 M |
-$164.80 M |
$4.90 M |
$296.42 M |
$192.18 M |
-$790,000.00 |
-$81.38 M |
$4.13 M |
-$6.71 M |
$30.40 M |
| Operating Expenses |
$4.78 B |
$3.49 B |
$3.89 B |
$2.60 B |
$2.41 B |
$1.97 B |
$1.82 B |
$1.48 B |
$1.37 B |
$1.16 B |
| Cost And Expenses |
$6.04 B |
$4.57 B |
$4.80 B |
$3.34 B |
$2.96 B |
$2.38 B |
$2.10 B |
$1.69 B |
$1.50 B |
$1.22 B |
| Interest Income |
$614.70 M |
$144.60 M |
$4.90 M |
$22.24 M |
$63.68 M |
$0.00 |
$11.75 M |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$44.10 M |
$54.80 M |
$61.50 M |
$58.15 M |
$58.50 M |
$34.12 M |
$57.55 M |
$81.43 M |
$84.21 M |
$72.86 M |
| Depreciation &
Amortization |
$181.30 M
|
$148.30 M
|
$125.60 M
|
$109.52 M
|
$106.94 M
|
$72.42 M
|
$61.40 M
|
$61.40 M
|
$62.34 M
|
$63.26 M
|
| EBITDA |
$4.61 B
|
$4.44 B
|
$2.92 B
|
$3.28 B
|
$1.56 B
|
$706.78 M
|
$103.26 M
|
$75.46 M
|
-$411.25 M
|
-$598.76 M
|
| EBITDA Ratio |
0.47 |
0.49 |
0.37 |
0.51 |
0.35 |
0.22 |
0.13 |
0.01 |
-0.46 |
-1.05 |
| Operating Income Ratio
|
0.44
|
0.48
|
0.37
|
0.46
|
0.29
|
0.21
|
0.05
|
0.01
|
-0.45
|
-1.19
|
| Total Other
Income/Expenses Net |
$72.30 M
|
-$75.00 M
|
-$51.70 M
|
$62.80 M
|
$197.42 M
|
-$34.91 M
|
-$138.93 M
|
-$77.30 M
|
-$90.92 M
|
-$42.46 M
|
| Income Before Tax |
$4.38 B |
$4.23 B |
$2.73 B |
$3.12 B |
$1.39 B |
$600.24 M |
-$15.69 M |
-$67.37 M |
-$559.58 M |
-$734.88 M |
| Income Before Tax Ratio
|
0.44
|
0.47
|
0.36
|
0.5
|
0.34
|
0.2
|
-0.01
|
-0.04
|
-0.54
|
-1.27
|
| Income Tax Expense |
$760.20 M |
$910.40 M |
$388.30 M |
$405.15 M |
$218.11 M |
-$1.49 B |
-$107.32 M |
$16.67 M |
$30.38 M |
$6.96 M |
| Net Income |
$3.62 B |
$3.32 B |
$2.34 B |
$2.71 B |
$1.18 B |
$2.10 B |
$263.48 M |
-$112.05 M |
-$558.12 M |
-$738.56 M |
| Net Income Ratio |
0.37 |
0.37 |
0.31 |
0.44 |
0.28 |
0.69 |
0.11 |
-0.07 |
-0.54 |
-1.27 |
| EPS |
14.05 |
12.97 |
9.09 |
10.44 |
4.58 |
8.25 |
1.06 |
-0.46 |
-2.32 |
-3.14 |
| EPS Diluted |
13.89 |
12.82 |
9.01 |
10.29 |
4.51 |
8.09 |
1.04 |
-0.46 |
-2.31 |
-3.14 |
| Weighted Average Shares
Out |
$257.70 M
|
$256.10 M
|
$257.70 M
|
$259.84 M
|
$256.73 M
|
$254.29 M
|
$248.86 M
|
$243.59 M
|
$240.84 M
|
$234.92 M
|
| Weighted Average Shares
Out Diluted |
$260.50 M
|
$259.10 M
|
$259.90 M
|
$263.40 M
|
$260.67 M
|
$259.19 M
|
$253.23 M
|
$244.69 M
|
$241.31 M
|
$235.31 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
